

RSV Prevention Products

Older Adults 60 years and older

- ABRYSVO (Pfizer): vaccine*
- AREXVY (GSK): vaccine


Infants and Young Children

- Nirsevimab (Beyfortus): immunization (monoclonal antibody) for all infants and high-risk young children
- Palivizumab (Synagis): immunization (monoclonal antibody) for high-risk infants and young children



*FDA approved for maternal immunization and awaiting CDC ACIP review

Similar Burden of RSV and Influenza Among Adults ≥ 65 years



¹Falsey et al, NEJM (2005); ²Adapted from Falsey et al, NEJM (2005); ³Estimated Influenza Disease Burden 2015-2016 through 2019-2020, CDC (2022): <https://www.cdc.gov/flu/about/burden/past-seasons.html>

Adults who may be at higher risk of RSV disease include persons with:



Chronic lung diseases
such as COPD and
asthma



Chronic cardiovascular
diseases such as congestive
heart failure and coronary
artery disease



Immune
compromise



Hematologic
disorders




Residents of nursing
homes and other long-
term care facilities



Neurologic disorders



Endocrine disorders
such as diabetes




Kidney and liver
disorders



Other underlying conditions or
factors that the provider
determines might increase the
risk of severe respiratory illness

RSV Hospitalizations in adults aged ≥ 65 years by season: RSV-NET 2017–2023



RSV-NET: unpublished data. Surveillance for 2017-18 through 2019-20 seasons were conducted from October – April; for 2020-21 and 2021-22 surveillance was conducted continuously from October – September. Data shown for 2022-23 season is from October – December 2022.

RSV Vaccines Approved for Adults Ages \geq 60 Years

AREXVY[®] (GSK)

- RSV vaccine, adjuvanted
 - Antigen: 120ug RSVpreF3
 - Adjuvant: AS01E[^]
- 1 dose
- Intramuscular injection
- Efficacy: 82.6% reduction in risk of RSV-associated lower respiratory tract disease*

ABRYSVO[®] (Pfizer)

- RSV vaccine, no adjuvant
 - Antigen: 60ug RSVpreF A and 60ug RSVpreF B
- 1 dose
- Intramuscular injection
- Efficacy: 85.7% reduction in risk of RSV-associated lower respiratory tract disease* with \geq 3 symptoms

*Lower respiratory tract disease signs/symptoms include cough, sputum, and difficulty breathing.

[^]Similar to adjuvant used for Shingrix (half dose of same components)

[AREXVY FDA Product Insert](#) | [ABRYSVO FDA Product Insert](#)

RSV Vaccines for Older Adults: Safety

AREXVY® (GSK)

- Safety:
 - injection site pain (60.9%)
 - fatigue (33.6%)
 - myalgia (28.9%)
 - headache (27.2%)
 - arthralgia (18.1%)
- Serious adverse events under monitoring:
 - Guillain-Barré Syndrome (GBS)
 - Acute disseminated encephalomyelitis (ADEM)
 - Supraventricular arrhythmias

ABRYSVO® (Pfizer)

- Safety:
 - pain at the injection site (10.5%)
 - fatigue (15.5%)
 - muscle pain (10.1%)
 - headache (12.8%)
- Serious adverse events under monitoring:
 - Guillain-Barré Syndrome (GBS) and other immune-mediated demyelinating conditions
 - Supraventricular arrhythmias

Older Adult RSV Vaccine Recommendations

- For the 2023–24 season, offer RSV vaccination to adults aged ≥ 60 years using shared clinical decision-making as early as vaccine supply becomes available and continue to offer vaccination to eligible adults who remain unvaccinated.
- Coadministration of RSV vaccines with other adult vaccines during the same visit is acceptable.
- Full recommendations in *7/2023 Morbidity and Mortality Weekly Report* (MMWR).

[CDC RSV Media Statement June 29, 2023](#)

[MMWR: Use of RSV Vaccines in Older Adults: ACIP Recommendations](#)

Shared Clinical Decision-Making Guidance

- The decision to vaccinate a patient should be based on a discussion between the provider and the patient, which might be guided by the patient's risk for disease and their characteristics, values, and preferences; the provider's clinical discretion; and the characteristics of the vaccine.
- As part of this discussion, providers and patients should consider the patient's risk for severe RSV-associated disease.
 - Persons with chronic medical conditions
 - Those who are frail or who are of advanced age*
 - Residents of nursing homes and long-term care facilities*

*limited enrollment of these populations in clinical trials

[MMWR: Use of RSV Vaccines in Older Adults: ACIP Recommendations](#)

[ACIP Shared Clinical Decision-Making Recommendations: Frequently Asked Questions](#)


Rationale for Recommendations

- Vaccination with a single dose of RSV vaccine demonstrated efficacy in preventing symptomatic RSV-associated LRTD among adults aged ≥ 60 years.
- Although trials were underpowered to estimate efficacy against RSV-associated hospitalization and death, trial data suggest that vaccination might prevent morbidity from RSV disease among adults aged ≥ 60 years.
- Both vaccines were well-tolerated with an acceptable safety profile.
- Serious neurologic conditions, including Guillain-Barré syndrome (GBS), have been reported very rarely after RSV vaccination in clinical trials. It is unclear whether the vaccine caused these events. Post-marketing surveillance over the next year or more expected to help clarify the existence of any potential risk.
- RSV vaccination in older adults should be targeted to those who are at highest risk for severe RSV disease and therefore most likely to benefit from vaccination.

[MMWR: Use of RSV Vaccines in Older Adults: ACIP Recommendations](#)

[CDC: RSV Vaccine Information Statement \(VIS\)](#)

Questions?

A flyer with a blue header and footer. The main body features a photograph of an elderly woman in a wheelchair being supported by a caregiver, both wearing face masks. Text on the flyer includes: 'Protect Against Flu, RSV, and COVID-19!', 'These diseases can be life-threatening', 'Protect Yourself and Your Community', a list of vaccines to ask for, and 'It's convenient and safe to receive all the vaccines you need on the same day!'. The footer contains the CDPH logo and the text 'IMM-1413 (8/23)'.

Protect Against Flu, RSV, and COVID-19!

These diseases can be life-threatening
Patients and staff depend on each other to prevent severe illness, hospitalization, and death.


Protect Yourself and Your Community
Ask your doctor or health team for:

- Flu vaccine
- COVID-19 vaccine(s)
- RSV vaccine (for people 60 years or older at high-risk)
- Other recommended vaccines such as pneumococcal, shingles, and Tdap vaccines.

It's convenient and safe to receive all the vaccines you need on the same day!

Get your flu, RSV, and COVID-19 vaccines at:

IMM-1413 (8/23)

 CDPH
California Department of Public Health

Visit this [Long-Term Care Facilities page](#) for more immunization resources.

[Flyer link](#)